Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
Shengli Xia(Henan Provincial Center for Disease Control and Prevention), Yuntao Zhang(National Vaccine and Serum Institute), Yanxia Wang(Henan Provincial Center for Disease Control and Prevention), Hui Wang(National Vaccine and Serum Institute), Yunkai Yang(National Vaccine and Serum Institute), George F. Gao(Chinese Center For Disease Control and Prevention), Wenjie Tan(Chinese Center For Disease Control and Prevention), Guizhen Wu(Chinese Center For Disease Control and Prevention), Miao Xu(National Institutes for Food and Drug Control), Zhiyong Lou(Tsinghua University), Weijin Huang(National Institutes for Food and Drug Control), Wenbo Xu(Chinese Center For Disease Control and Prevention), Baoying Huang(Chinese Center For Disease Control and Prevention), Huijuan Wang(National Vaccine and Serum Institute), Wei Wang(National Vaccine and Serum Institute), Wei Zhang(Henan Provincial Center for Disease Control and Prevention), Na Li(National Vaccine and Serum Institute), Zhiqiang Xie(Henan Provincial Center for Disease Control and Prevention), Ling Ding(National Vaccine and Serum Institute), Wangyang You(Henan Provincial Center for Disease Control and Prevention), Yuxiu Zhao(National Vaccine and Serum Institute), Xuqin Yang(National Vaccine and Serum Institute), Yang Liu(National Vaccine and Serum Institute), Qian Wang(National Vaccine and Serum Institute), Lili Huang(Henan Provincial Center for Disease Control and Prevention), Yongli Yang(Zhengzhou University), Guangxue Xu(Tsinghua University), Bojian Luo, Wenling Wang(Chinese Center For Disease Control and Prevention), Peipei Liu(Chinese Center For Disease Control and Prevention), Wanshen Guo(Henan Provincial Center for Disease Control and Prevention), Xiaoming Yang(National Vaccine and Serum Institute)
Cited by 1,209Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis